A Methodology Study in Healthy Subjects to Evaluate the Effect of AZD8309 After Nasal Administration of Lipopolysaccharide (LPS)

Completed 20 enrolled AstraZeneca

RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of this methodology study is to evaluate the effect of AZD8309 on cells and inflammatory biomarkers in nasal lavage and blood after nasal challenge with lipopolysaccharide (LPS)

Timeline

Start: 2009-03
Primary completion: —
Completion: 2009-10

Publications

Leaker BR, Barnes PJ, O'Connor B. Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respir Res. 2013 Dec 16;14(1):137. doi: 10.1186/1465-9921-14-137.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	AZD8309	Unknown	300 mg	Oral

Indications

No indication recorded.